Skip to main content
. Author manuscript; available in PMC: 2016 May 4.
Published in final edited form as: Lancet Haematol. 2015 Mar 20;2(3):e118–e128. doi: 10.1016/S2352-3026(15)00021-6

Figure 1. Long term outcomes according to four TKI modalities (Imatinib 400, Imatinib 800, Dasatinib and Nilotinib).

Figure 1

A) Event free survival (EFS); median survival not reached in all 4 TKI modalities B) Failure free survival (FFS); median survival not reached for dasatinib and nilotinib and 94.4, 127.3 months in imatinib 400 and 800 respectively C) Transformation free survival (TFS); median survival not reached in all and D) Overall survival (OS); median survival not reached in all 4 TKI modalities. Corresponding Hazard ratios for each outcome according to TKI modality are shown in univariate analysis in Table-2, supplemental tables 1, 2 and 3 for EFS, FFS, TFS and OS respectively.